MEMORANDUM FOR SGVP  
ATTN: CAPT JULIE MENEGAY

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

1. Your paper, entitled **Influenza-Like Illness in HIV-Infected Active Duty Members Receiving Live Attenuated Versus Inactivated Influenza Vaccine** presented at **Alcalde Southwest Leadership Conference, Frisco, TX 19-21 April 2016** with MDWI 41-108, and has been assigned local file #16112.

2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.

3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are 59 MDW staff member, we can forward your request for funds to the designated wing POC.

4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC  
Director, Clinical Investigations & Research Support

*Warrior Medics – Mission Ready – Patient Focused*
PROCESSING OF PROFESSIONAL MEDICAL RESEARCH PUBLICATIONS/PRESENTATIONS

TO: Clinical Research Division/SGVU
(59 MDW/SGVU)
FROM: Author's Name, Rank, Grade, Office Symbol
Julie Menegay, Capt, O-3, SGVPI

PROTOCOL NUMBER:
C.2015.170d / IRBNet # 417804

PROTOCOL TITLE - [NOTE: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.]
Health and Wellness Outcomes in the United States Active Duty Service Member Population

1. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED
INFLUENZA-LIKE ILLNESS IN HIV-INFECTED ACTIVE DUTY MEMBERS RECEIVING LIVE ATTENUATED VERSUS INACTIVATED INFLUENZA VACCINE

2. FUNDING RECEIVED FOR THIS STUDY?  [X] YES  [ ] NO  FUNDING SOURCE: 

3. IS THIS MATERIAL CLASSIFIED?  [ ] YES  [X] NO

4. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.?  [ ] YES  [X] NO
NOTE: If the answer is "YES" then attach a copy to the Agreement to the Publications/Presentations Request Form.

5. MATERIAL IS FOR (Check appropriate box or boxes for approval with this request.)
(ATTACH COPY OF MATERIAL TO BE PUBLISHED/PRESENTED)
[ ] DOMESTIC RELEASE  [X] FOREIGN RELEASE

   [ ] PUBLICATION/JOURNAL (List intended publication/journal)
   [ ] PUBLICATION ABSTRACT (List intended journal)
   [ ] POSTER (To be demonstrated at meeting/Name of Meeting, City, State, and Date of Meeting)
   [ ] PLATFORM PRESENTATION (At civilian institution/Name of Meeting, State, Date of Meeting)
   [X] OTHER (Describe: Name of Meeting, City, State, and Date of Meeting)
       Acldss Southwest Leadership Conference, Frisco, Texas 19-21 April 2016

6. WHAT IS THE EXPECTED DATE YOUR PRESENTATION/PUBLICATION WILL BE SUBMITTED TO THE DEFENSE TECHNICAL INFORMATION CENTER (DTIC)?
   Feb 29, 2016

POINT OF CONTACT
7. WHO IS THE PRIMARY 59 MDW POINT OF CONTACT?  (Last, First, Mi.) (Include email)
Menegay, Julie L; julie.l.menegay.mil@mail.mil

DUTY PHONE/PAGER No.
210-916-3455

AUTHORSHIP AND CO-AUTHOR(S) (List in the order they will appear in the manuscript)

<table>
<thead>
<tr>
<th>LAST NAME, FIRST NAME AND MI.</th>
<th>GRADE/RANK</th>
<th>SQUADRON/GROUP/OFFICE SYM</th>
<th>INSTITUTION (If not 59 MDW)</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Primary/Corresponding author</td>
<td>O-3/Capt</td>
<td>959th CPS/SGVPI</td>
<td></td>
</tr>
<tr>
<td>b.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>d.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>e.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>f.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>g.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

I CERTIFY ANY HUMAN OR ANIMAL RESEARCH RELATED STUDIES WERE APPROVED AND PERFORMED IN STRICT ACCORDANCE WITH 32 CFR 219, AFMAN 40-401, IP AND 59 MDW 41-108. I HAVE READ THE FINAL VERSION OF THE ATTACHED MATERIAL AND CERTIFY THAT IT IS AN ACCURATE MANUSCRIPT FOR PUBLICATION AND/OR PRESENTATION.

AUTHOR’S PRINTED NAME/RANK/GRADE
Julie Menegay, Capt, O-3

AUTHOR’S SIGNATURE
MENEGAY.JULIE.L.1393077227
DATE
Mar 1, 2016

APPROVING AUTHORITY’S PRINTED NAME, RANK, TITLE
Fenzl, Heather, Maj, USAF, BSC
Associate Program Director Pharmacy Practice Residency

APPROVING AUTHORITY’S SIGNATURE
FENZL.HEATHER.WINFREE.1263938352
DATE
4 Mar 2016

59 MDW Form 3039 (DATE)
Supersedes 59 MDW Form 3039, 20131018
Page 2 of 3
### PROCESSING OF PROFESSIONAL MEDICAL RESEARCH PUBLICATIONS/PRESENTATIONS

**1st ENDORSEMENT (SGVU Use Only)**

<table>
<thead>
<tr>
<th>TO: Clinical Research Division</th>
</tr>
</thead>
<tbody>
<tr>
<td>(59 MDW/SGVU)</td>
</tr>
<tr>
<td>Contact 292-7141 for email instructions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1. DATE RECEIVED</th>
<th>2. ASSIGNED PROCESSING REQUEST FILE NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>3/7/2016</td>
<td>16119</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. DATE REVIEWED</th>
<th>4. DATE FORWARDED TO PA</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 Mar 2016</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>NO</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔ APPROVED</td>
</tr>
</tbody>
</table>

The author added the DoD disclaimer statement to his article. The article is approved.

---

**PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER**

Rocky Calcote, PhD
Clinical Research Administrator

**DATE**

**SIGNATURE OF REVIEWER**

CALCOTE, ROCKY D. 1178245844

**2nd ENDORSEMENT (PA Use Only)**

<table>
<thead>
<tr>
<th>TO: 59 MDW OFFICE OF PUBLIC AFFAIRS (PA)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>1. DATE RECEIVED</th>
<th>2. DATE FORWARDED TO 59 MDW/SGVU</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>6. COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔ APPROVED</td>
</tr>
</tbody>
</table>

(in compliance with security and policy review directives)

---

**PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER**

Christopher Carwile, TSgt/E-6, NCOIC, PA

**DATE**

**SIGNATURE OF REVIEWER**

CARWILE, CHRISTOPHER S. 1280477229

**3rd ENDORSEMENT (SGVU Use Only)**

<table>
<thead>
<tr>
<th>TO: 59 MDW/SGVU</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>2. SENIOR AUTHOR NOTIFIED BY PHONE OF APPROVAL OR DISAPPROVAL:</th>
</tr>
</thead>
<tbody>
<tr>
<td>YES  NO  Could not be reached  Left message</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. DATE WRITTEN NOTICE OF APPROVAL AND CLEARANCE MAILED TO AUTHORE:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>4. COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔ APPROVED</td>
</tr>
</tbody>
</table>

---

**PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER**

**SIGNATURE OF REVIEWER**

**DATE**
INFLUENZA-LIKE ILLNESS IN HIV-INFECTED ACTIVE DUTY MEMBERS RECEIVING LIVE ATTENUATED VERSUS INACTIVATED INFLUENZA VACCINE.

Julie L. Menegay, Jason F. Okulicz, San Antonio Military Medical Center, Fort Sam Houston, TX

PURPOSE: To evaluate influenza vaccine administration practices and the incidence of influenza-like illness (ILI) following vaccination in HIV-infected individuals. The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) guidelines recommend inactivated influenza vaccine (IIV) for all HIV-infected individuals, however data is limited on adverse effects of inactivated influenza vaccine (IIV) vs live attenuated intranasal influenza vaccine (LAIV) in HIV-infected persons.

METHODS: A retrospective database review of influenza vaccination in active duty United States Air Force (USAF) patients with HIV infection immunized between 1996-2012 was performed. Influenza vaccination history, including receipt of LAIV or IIV after HIV diagnosis, and CD4 count and viral load at time of vaccination were evaluated. The proportion of patients with ILI diagnoses within 30 days after vaccination with either IIV or LAIV was assessed by ICD-9 codes.

RESULTS: A total of 592 patients were included; 269 (45.4%) received LAIV after HIV diagnosis. Of these, 167 (62%) patients received LAIV during ≥2 doses in separate influenza seasons. The mean CD4 count at time of first LAIV vaccination was 555 ± 240 cells/μL. Data evaluating ILI diagnoses after LAIV or IIV vaccination is currently pending.

CONCLUSION: In contrast to CDC recommendations, nearly half of all USAF patients with HIV infection received LAIV at least once after HIV diagnosis. Although LAIV administration may or may not show an increased frequency of ILI following vaccination, further education is needed to ensure that LAIV is avoided in USAF members with HIV infection.

The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components.
MEMORANDUM FOR 59 MDW/SGVPI

FROM: 502 ISG/JA

SUBJECT: Ethics Review for Presentation Approval Request

1. The abstract titled “Health and Wellness Outcomes in the United States Active Duty Service Member Population” was submitted for legal review. There are no apparent conflicts of interests and the abstract includes the required disclaimer. This abstract may be presented at the society meeting.

2. FACTS: The abstract titled “Health and Wellness Outcomes in the United States Active Duty Service Member Population” was submitted by Capt Julie Menegay. Capt Menegay is a member of 59 MDW/SGVPI. Capt Menegay plans to present this research at the Alcalde Southwest Leadership Conference in Frisco, TX on 19-21 April 2016.

3. LAWS AND REGULATIONS: DoD 5500.07-R, Joint Ethics Regulation (JER), section 3-305 lays out rules governing “Teaching, Speaking and Writing.” If the abstract will include the service member's rank or title and "deal in significant part with any ongoing or announced policy, program or operation" of the Air Force, the presenter is required to include a disclaimer that states the "views presented are those of the speaker or author and do not necessarily represent the views of DoD or its Components."

4. ANALYSIS: The abstract deals "in significant part with any ongoing or announced policy, program or operation" of the Air Force. The author’s affiliation and/or rank will be included in the abstract, and the case study information was obtained as part of military medical practice. Capt Menegay properly includes the required disclaimer that the views presented are those of the author and do not necessarily represent the views of DoD or its Components on the abstract. Any resultant poster, slide or oral presentation must also include the required disclaimer. A Public Affairs review will be needed if it has not already been obtained. There are no apparent conflicts of interest that would prohibit presentation of this research at this professional meeting.
5. **CONCLUSION:** The abstract presented for review included the disclaimer required by the JER. There do not appear to be any conflicts of interest. Any poster, slide or verbal presentation must also include disclaimer language. If you have any questions, please call the undersigned at 671-3362.


JESSE BOLAÑOS  
Legal Intern

I concur.


ARLENE R. CHRISTILLES  
Chief, Civil Law